Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part Open-Label Phase I Study of TAVO412 in Patients with Advanced or Metastatic Solid Tumors Who Progressed on Prior Approved Standard of Care Therapy

NCT05548634 is registered in ClinicalTrials.gov with Tavotek Biotherapeutics as lead sponsor.

NCT NCT05548634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05548634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part Open-Label Phase I Study of TAVO412 in Patients with Advanced or Metastatic Solid Tumors Who Progressed on Prior Approved Standard of Care Therapy
Lead sponsor
Tavotek Biotherapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 8, 2023
Completion date
June 1, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer